Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dac-MSCs + Fitostimoline
- Development stage
- Unknown
- Lead developer
- Universidad Autónoma de Bucaramanga
- Modality
- Small Molecules, Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
dac-MSCs + Fitostimoline is an investigational combination therapy being developed by the Universidad Autónoma de Bucaramanga for the treatment of chronic diabetic foot ulcers. The therapy consists of acellular derivatives from bone marrow-derived mesenchymal stromal cells (MSCs) that have been pre-treated with the epigenetic modulator decitabine (dac-MSCs), combined with Fitostimoline (an extract of *Triticum vulgare*). Decitabine treatment is intended to enhance the regenerative potential of the MSC secretome. The combination aims to promote wound healing through multiple biological pathways, including enhanced re-epithelialization, stimulation of angiogenesis, and overall tissue regeneration. It is currently being evaluated in Phase 1/2 clinical trials to compare the efficacy of acellular derivatives against whole cell-based therapies and standard care.
- Brand names
- Fitostimoline
- Other names
- decitabine-treated mesenchymal stromal cell derivatives + Triticum vulgaredac-MSCs + Triticum vulgare
Beyond the preview
Go deeper on dac-MSCs + Fitostimoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dac-MSCs + Fitostimoline.